Epclusa (sofosbuvir/velpatasvir) is the first FDA-approved hepatitis C treatment that can cure all six major genotypes in a single 12-week course. Its cure rate is extraordinary — sustained virologic response in 95 to 99 percent of patients, the medical definition of a cure. The obstacle for most patients is not the medicine but its price: without insurance or assistance, a full 84-tablet course of Epclusa carries a US list price near $74,760. SunnyPharma compiled this guide from manufacturer price disclosures, FDA data, and AASLD-IDSA guidance.
This page breaks down exactly what Epclusa costs in the USA in 2026 — brand versus generic, with and without insurance — and explains every legitimate pathway that brings most patients to $0.
This page is part of SunnyPharma’s complete guide to HCV medications, costs, and patient assistance — compare every hepatitis C direct-acting antiviral and find free or low-cost treatment options in the US.
List prices are wholesale acquisition cost (WAC) and are rarely what patients pay. Source: gileadpriceinfo.com (WAC Jan 1, 2026). See insurance and assistance sections below.
- List price is not what most patients pay — assistance brings the great majority to $0–$5/month.
- Brand WAC is $24,920 per 28-day supply, about $74,760 for a full 12-week course.
- The authorized generic (Asegua) lists near $24,000 per course — same ingredients, same safety profile.
- Most Medicaid patients pay $0; about 80% of Medicare patients pay $15 or less per month.
- Pan-genotypic: treats all six HCV genotypes in adults and children aged 3 and older.
Do not pay list price. The ~$74,760 brand WAC is a reference number, not a fixed cash price. Uninsured patients have multiple pathways — including free medication through Gilead’s Patient Assistance Program — that should be explored before paying out of pocket.
What Is Epclusa?
Epclusa is a once-daily fixed-dose tablet combining sofosbuvir 400 mg and velpatasvir 100 mg. Manufactured by Gilead Sciences and FDA-approved on June 28, 2016, it is a direct-acting antiviral (DAA). Unlike older interferon-based regimens, which caused significant side effects and cured fewer patients, Epclusa is taken orally for 12 weeks with high tolerability and pan-genotypic coverage.
Brand and authorized generic are clinically identical. The authorized generic, sofosbuvir/velpatasvir from Asegua Therapeutics (a Gilead subsidiary), contains the same active ingredients, works the same way, and carries the same safety profile as brand Epclusa. For patients seeking to reduce cost, the generic is the first option to explore.
Epclusa Cost in the USA: Brand vs. Generic (2026)
The price of Epclusa varies by whether you buy the brand or the authorized generic, and whether you use insurance or a discount program. The table below summarizes 2026 reference points.
| Product | Supply | Price | Notes |
|---|---|---|---|
| Brand Epclusa | 28 tablets (1 month) | $24,920 | WAC as of Jan 1, 2026 (Gilead) |
| Brand Epclusa | 84 tablets (full course) | ~$74,760 | List price; few patients pay this |
| Generic (Asegua) | 84 tablets (full course) | ~$24,000 | Authorized generic list price |
| Generic + discount card | 28 tablets (1 month) | ~$7,683 | Pharmacy discount-card cash price, 2026 |
| Brand + copay card | Per month | $5 | Commercially insured patients only |
| Medicare Part D | Full course | ≤$2,000 OOP | 2025 Part D cap; ~80% pay ≤$15/month |
| Medicaid | Full course | $0 | Most Medicaid beneficiaries pay $0 |
Important context: wholesale acquisition cost (WAC) is the manufacturer’s published reference price — rarely what a patient actually pays. Insurance-negotiated rates, copay assistance, and discount programs reduce out-of-pocket cost dramatically for most patients.
Epclusa Cost With Insurance
Commercial (Employer or Marketplace) Insurance
Epclusa and its authorized generic are covered by most commercial plans. Your actual cost depends on your plan’s formulary tier, deductible, and coinsurance. Most plans require prior authorization — your prescriber submits documentation of your hepatitis C diagnosis and genotype before the pharmacy dispenses.
If you have commercial insurance, you are likely eligible for the Gilead Epclusa copay coupon through Support Path. It can reduce your monthly cost to as little as $5, covering up to 25% of the catalog price for three bottles (a full course), valid six months from first redemption.
Copay accumulator and maximizer programs: some insurers run programs that stop manufacturer copay assistance from counting toward your deductible. If your plan does this, your copay savings may be capped. Confirm your benefit level with Support Path before filling your first prescription. Learn more in our copay accumulator guide.
Medicare Part D and Medicare Advantage
Epclusa is covered by most Medicare Part D and Medicare Advantage plans. The 2025 Part D reform introduced a $2,000 annual out-of-pocket cap, which sharply limits Medicare spending on high-cost specialty drugs. Per Gilead, about 80% of Medicare patients pay $15 or less per month for Epclusa.
Beneficiaries who qualify for Extra Help (the Low Income Subsidy) can reduce costs further to roughly $4 to $9 per month. Manufacturer copay coupons cannot be used with Medicare, but Gilead’s Support Path offers alternative pathways for government-insured patients.
Medicaid
Medicaid coverage for Epclusa is strong across states. Per Gilead’s 2025 data, most people with Medicaid coverage pay $0 for a full course of Epclusa or its authorized generic, and some states eliminate copays entirely. Contact your state Medicaid office or Support Path for state-specific guidance.
Epclusa Cost Without Insurance
Uninsured patients face the highest sticker prices, but several programs exist specifically to provide Epclusa at reduced or no cost. Do not pay the published list price before exhausting these options.
- Gilead Support Path Patient Assistance Program: provides Epclusa or the authorized generic at no cost to eligible uninsured patients who meet income criteria. Enroll at MySupportPath.com.
- Pharmacy discount card (generic): reduces the 28-day supply of generic sofosbuvir/velpatasvir to roughly $7,683 at participating pharmacies, no insurance required — about $23,000 for a full course. Still far above $0, so use only if you do not qualify for PAP or Medicaid.
- AIDS Drug Assistance Program (ADAP): patients with HIV/HCV co-infection may qualify for Epclusa through state ADAP programs. Contact your state health department.
- Federally Qualified Health Centers (FQHCs): community health centers in the 340B program can access Epclusa at substantially reduced cost. Find one via the HRSA health center finder.
- ACA Marketplace enrollment: enrolling in a Marketplace plan, especially with income-based subsidies, may make Epclusa coverage accessible at a low premium. Check options at healthcare.gov.
How to Reduce Your Epclusa Cost: By Coverage Type
The right pathway depends on your insurance status.
If You Have Commercial Insurance
Have your prescriber request prior authorization before filling. Once approved, enroll in the Epclusa copay coupon program at MySupportPath.com — eligible patients pay as little as $5/month. If your insurer uses a copay accumulator, confirm your adjusted benefit with Gilead first.
If You Have Medicare
Check whether your Part D or Advantage plan covers Epclusa. Your maximum out-of-pocket for covered drugs under Part D is $2,000 in 2025. If your income is limited, apply for Extra Help at ssa.gov, which can reduce costs to $4–$9/month. Support Path can help navigate Medicare-specific options.
If You Have Medicaid
Confirm your state Medicaid plan covers Epclusa (most do). Most beneficiaries pay $0. If your state does not cover it, contact Support Path to explore alternatives, including the Patient Assistance Program.
If You Are Uninsured
Apply immediately for the Gilead Support Path Patient Assistance Program at MySupportPath.com. If you do not meet income criteria, use a pharmacy discount card for the authorized generic, or contact an FQHC about 340B pricing.
The list price of Epclusa is $24,920 per month. The list price is not typically the price a patient pays — most pay between $0 and $5 per month. — Gilead Sciences, gileadpriceinfo.com (January 2026)
Gilead Support Path: Patient Assistance Program
Gilead Support Path is the primary financial assistance resource for patients who cannot afford Epclusa. It has two pathways based on insurance status.
| Program | Who Qualifies | Benefit | How to Apply |
|---|---|---|---|
| Copay Coupon | Commercially insured (not Medicare/Medicaid) | As low as $5/month | MySupportPath.com |
| Patient Assistance | Uninsured or underinsured; meets income criteria | Free medication | MySupportPath.com |
Support Path specialists can run a benefits investigation, verify coverage, and guide enrollment. Apply online at MySupportPath.com, or ask your clinic’s social work team to help with the application.
Epclusa vs. Mavyret vs. Harvoni: Cost Comparison
Epclusa is not the only DAA for chronic hepatitis C. The most common alternatives are Mavyret (glecaprevir/pibrentasvir, AbbVie) and Harvoni (ledipasvir/sofosbuvir, Gilead). Understanding how they compare supports a more informed conversation with your physician.
| Medication | Genotypes | Duration | List Price (Full Course) |
|---|---|---|---|
| Epclusa (sofosbuvir/velpatasvir) | 1–6 (pan-genotypic) | 12 weeks | ~$74,760 |
| Mavyret (glecaprevir/pibrentasvir) | 1–6 (pan-genotypic) | 8–16 weeks | ~$26,400 (8-wk) |
| Harvoni (ledipasvir/sofosbuvir) | 1, 4, 5, 6 | 8–12 weeks | ~$66,000–$94,500 |
Note: list-price comparisons can mislead because insurance-negotiated rates and assistance programs differ by payer. The clinical choice depends on your genotype, cirrhosis status, and prior treatment — always discuss alternatives with your prescriber. See our full HCV medications guide and Harvoni cost and access guide.
Frequently Asked Questions
Without insurance, the brand-name list price for Epclusa is approximately $74,760 for a full 12-week course (84 tablets), based on the wholesale acquisition cost of $24,920 per 28-tablet supply as of January 1, 2026. The authorized generic, sofosbuvir/velpatasvir from Asegua Therapeutics, has a list price of roughly $24,000 for the full course. A pharmacy discount card can reduce the generic cash price to around $7,683 for a 28-day supply. Most patients never pay these figures once assistance is applied.
Yes. Asegua Therapeutics, a subsidiary of Gilead Sciences, makes an authorized generic of Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg). It contains the identical active ingredients, works the same way, and has the same safety profile as the brand. The authorized generic list price is approximately $24,000 for the full 84-tablet course; with a pharmacy discount card the cash price for a 28-day supply can drop to around $7,683.
Epclusa is covered by most Medicare Part D and Medicare Advantage plans. Since 2025, Medicare Part D has a $2,000 annual out-of-pocket cap, which sharply limits what Medicare patients pay for high-cost specialty drugs. According to Gilead, about 80% of Medicare patients pay $15 or less per month for Epclusa. Manufacturer copay coupons cannot be used with Medicare, but Gilead’s Support Path patient assistance program may provide alternative help.
Most Medicaid plans cover Epclusa or its authorized generic. According to Gilead’s 2025 data, most people with Medicaid coverage pay $0 for a full course of Epclusa or its authorized generic, and some state programs eliminate copays altogether. Coverage rules vary by state; contact your state Medicaid office or Gilead Support Path for plan-specific details.
Gilead Support Path is the manufacturer’s financial assistance program for Epclusa. For commercially insured patients, a copay coupon can reduce the monthly cost to as little as $5. For uninsured or underinsured patients who meet income criteria, the Support Path Patient Assistance Program can provide Epclusa at no cost. Enroll online at MySupportPath.com.
Commercially insured patients (employer-sponsored or marketplace insurance, not Medicare or Medicaid) may qualify for the Epclusa copay coupon program through Gilead Support Path. Eligible patients can pay as little as $5 per month. The coupon covers up to 25% of the catalog price for three bottles, valid for six months from first redemption. Enroll at MySupportPath.com.
Epclusa is pan-genotypic, meaning it treats all six major hepatitis C genotypes: 1, 2, 3, 4, 5, and 6. It is approved for adults and children aged 3 and older who weigh at least 17 kg (37 lbs), with or without compensated cirrhosis. Children who cannot swallow tablets may use Epclusa oral pellets at weight-appropriate doses.
All three are direct-acting antivirals that cure hepatitis C. Epclusa (pan-genotypic, 12 weeks) has a US list price near $74,760 per course. Mavyret (pan-genotypic, often 8 weeks) is the lowest brand list price at about $26,400 for an 8-week course. Brand Harvoni (genotypes 1, 4, 5, 6) is the highest at roughly $94,500 for a 12-week course. List price rarely reflects what patients pay; the clinical choice depends on genotype, cirrhosis status, and prior treatment, and is made by your physician.
How we reviewed this article:
SunnyPharma follows strict sourcing guidelines and relies on manufacturer price disclosures, government agencies (FDA, CMS, HRSA), and medical associations (AASLD, IDSA). We use only credible, verifiable sources to ensure accuracy.
Read our editorial policy →Sources & References
- Gilead Sciences — EPCLUSA Cost Information (WAC as of Jan 1, 2026): gileadpriceinfo.com
- Gilead Sciences — Save on EPCLUSA (Medicaid $0, Support Path): epclusa.com
- Gilead Support Path — patient assistance and copay program: mysupportpath.com
- FDA — Epclusa Prescribing Information: accessdata.fda.gov
- AASLD-IDSA HCV Guidance — testing, managing, treating hepatitis C: hcvguidelines.org
- CMS — Medicare Part D $2,000 out-of-pocket cap (2025): cms.gov
- HRSA — 340B Drug Pricing Program: hrsa.gov
- HRSA — Find a Health Center (FQHC locator): findahealthcenter.hrsa.gov
- HealthCare.gov — ACA Marketplace enrollment: healthcare.gov